Active substance
Results for the substance tildrakizumab
2 results
About this active substance
Tildrakizumab is a monoclonal antibody used for the treatment of moderate-to-severe plaque psoriasis in adults. It works by blocking interleukin-23 (IL-23), a protein involved in the inflammatory process associated with psoriasis.
The medication is administered via subcutaneous injection, following a schedule determined by a doctor. Typically, the first two doses are given four weeks apart, followed by maintenance doses every 12 weeks.
Patients should be monitored for potential side effects, such as injection site reactions, respiratory infections, or headaches. It is important for patients to inform their doctor of any unusual symptoms.
Common side effects include upper respiratory tract infections, headaches, and injection site reactions. In rare cases, severe allergic reactions or serious infections may occur. Patients should be informed of these risks before starting treatment.
The medication is administered via subcutaneous injection, following a schedule determined by a doctor. Typically, the first two doses are given four weeks apart, followed by maintenance doses every 12 weeks.
Patients should be monitored for potential side effects, such as injection site reactions, respiratory infections, or headaches. It is important for patients to inform their doctor of any unusual symptoms.
Common side effects include upper respiratory tract infections, headaches, and injection site reactions. In rare cases, severe allergic reactions or serious infections may occur. Patients should be informed of these risks before starting treatment.